Quick Notes for Sept. 28, 2023

By PacConAdmin | September 28, 2023 | 0

Our coverage includes EMA’s revocation of conditional marketing authorization for Blenrep, FDA approvals for Pfizer’s Bosulif and Viatris/Ocuphire Pharma Ryzumvi, and the FY 2024 priority review voucher fee rate.
Source: Drug Industry Daily

Posted in Uncategorized and tagged

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.